Previous 10 | Next 10 |
2024-02-18 23:32:12 ET Summary Royalty Pharma delivered outstanding results in 2023 and deployed capital in key value-enhancing transactions. The company increased its dividend per share by 5% and reported adjusted cash receipts that exceeded internal expectations. Royalty Pha...
2024-02-15 13:39:09 ET Royalty Pharma PLC (RPRX) Q4 2023 Earnings Conference Call February 15, 2024, 8:00 a.m. ET Company Participants Pablo Legorreta - Founder, Chairman & CEO Chris Hite - Vice Chairman & EVP Terrance Coyne - EVP & CFO Marshall U...
Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023 Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023 Announced transactions of up to $4.0 billion in 2023 Full year 2024 guidance: Portfolio Rece...
2024-02-11 08:19:38 ET Summary A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates. Companies with upcoming pay dates. Introduction The D...
2024-02-08 09:10:29 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips The technology applied in the field of medicine undoubtedly surprises more and more investors every day. As technology advances in the world, biotech companies are in charge of applying it to i...
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous...
2024-01-25 04:45:00 ET Summary Patient Capital Management are long-term, contrarian, value investors focusing on growing wealth through Time, not Timing. We operate with the singular purpose of serving clients and helping them enhance their long term investment returns. The strate...
2024-01-22 07:13:56 ET Summary Royalty Pharma is a unique pharmaceutical company that diversifies investments in market-leading or late-stage development therapies. RPRX has a dominant position in the pharmaceutical royalty market and shares in the profits of successful pharmaceut...
2024-01-19 08:24:57 ET More on Royalty Pharma Royalty Pharma: Post Q3 Earnings, We Reiterated Our Strong Buy Royalty Pharma PLC (RPRX) Q3 2023 Earnings Call Transcript Teva inks $125M deal with Royalty Pharma to develop antipsychotic drug Royalty Pharma Q3 20...
2024-01-11 04:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the...